The present invention investigates the effects of hypertonicity on adipocytes, revealing its role in inducing the release of mitochondrial extracellular vesicles (MEVs). This release subsequently enhances the secretion of TNF-, a pro-inflammatory cytokine crucial during stress responses, thereby activating the Wnt/-catenin signaling pathway responsible for adipocyte dedifferentiation. Through the present method, hypertonicity induces MEVs release and TNF- secretion, ultimately modulating Wnt/-catenin signaling and promoting adipocyte dedifferentiation, offering promising therapeutic implications.

A preparation method and applications of rejuvenated and regenerative fibroblasts, where the rejuvenated and regenerative fibroblasts are prepared from normal fibroblasts by inhibiting the JAK-STAT signaling pathway. The rejuvenated and regenerative fibroblasts are prepared by treating the target cells with a small molecular combination, a cytokine combination or a recombinant protein combination. This application further provides an application of the rejuvenated and regenerative fibroblasts in the reprogramming or rejuvenation of cells, tissues, organs and organisms.

A method of using factor rich product from umbilical cord mesenchymal stem cells to increase collagen and elastin in adult human skin.

Disclosed in the present invention is a genetically engineered cell, expressing an exogenous receptor that specifically binds to a target antigen and exogenous CCL21, and capable of further expressing an IL-7R binding protein or exogenous IL-7 that promotes cell proliferation. Also disclosed are an expression construct comprising an exogenous CCL21 expression cassette, and a vector containing same, a virus, and a pharmaceutical composition comprising said cell. Also disclosed is an application for the cell, the expression construct, the vector, and the virus in the preparation of drugs for inhibiting tumours or inhibiting pathogens.

Factor rich compositions produced from umbilical cord (UC) mesenchymal stem cells (MSCs) are described. Secretory UC MSCs in serum free culture conditions produce a factor rich conditioned medium which may be concentrated and filtered to obtain clinical grade products.

The present invention provides methods of expanding T cells from a non-haematopoietic tissue source. Further provided are compositions of expanded T cells and methods of using the expanded T cells (e.g., a part of an adoptive T cell therapy).

The present invention provides a method for producing a T cell from an induced pluripotent stem cell, wherein the induced pluripotent stem cell is derived from a cell other than an T cell.

The present invention relates to the treatment of corneal endothelial cells in corneal disease and/or dysfunction. Further, the present invention relates to a method of preparing corneal endothelial cells in vitro.

The present invention provides a method for producing a natural killer cell from an iPS (Induced pluripotent stem) cell, comprising steps of: (i) contacting an iPS cell with a composition comprising a GSK-3 inhibitor and a ROCK inhibitor to obtain an embryoid body, (ii) contacting the embryoid body with a composition comprising a TGF receptor inhibitor to obtain a hematopoietic progenitor cell, (iii) culturing the hematopoietic progenitor cell to obtain a lymphocyte progenitor cell, and (iv) differentiating and expanding the lymphocyte progenitor cells to a natural killer cell.

The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and/or a label as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy diagnosis and in particular for diagnosis of cancer, particularly metastatic cancer, in particular for therapy of cancer.